UNITED STATES PATENT AND TRADEMARK OFFICE

I, Elaine Patricia PARRISH BSc, PhD,

translator to RWS Group Ltd, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England declare;

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.

2. That I am well acquainted with the French and English languages.

3. That the attached is, to the best of my knowledge and belief, a true translation into the English language of the accompanying copy of the specification filed with the application for a patent in France on 6 August 1999 under the number 99/10,378 and the official certificate attached hereto.

4. That I believe that all statements made herein of my own knowledge are true and that all statements made on information and belief are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application in the United States of America or any patent issuing thereon.

E Parrish

For and on behalf of RWS Group Ltd

The 6th day of December 2005

FRENCH REPUBLIC

INPI

INSTITUT
NATIONAL DE
LA PROPRIETE
INDUSTRIELLE

PATENT

UTILITY CERTIFICATE - CERTIFICATE OF ADDITION

OFFICIAL COPY

The Director-General of the Institut National de la Propriété Industrielle certifies that the attached document is a true copy of an application for industrial property titleright filed at the Institute.

Drawn up in Paris, 23 OCT. 2001

On behalf of the Director-General of the
Institut National de la Propriété Industrielle
The Patent Department Head

(signature)
Martine PLANCHE

INSTITUT
NATIONAL DE
LA PROPRIETE
INDUSTRIELLE

NATIONAL PUBLIC ESTABLISHMENT

REGISTERED OFFICE
26bis, rue de Saint Petersbourg
75800 PARIS Cédex 08
Telephone: 33 (1) 53 04 53 04
Fax: 33 (1) 42 93 59 30
www.inpi.fr

CREATED BY LAW

INPI
INSTITUT NATIONAL DE LA PROPRIETE INDUSTRIELLE

26 bis, rue de Saint Pétersbourg
75800 Paris Cedex 08
Telephone: 01 53 04 53 04 Tel fax. 01 42 93 59 30

PATENT, UTILITY CERTIFICATE

Intellectual Property Code - Book VI

Cerfa
No. 55-1328

REQUEST FOR GRANT

Confirmation of filing by fax ☐

This form is to be completed in black ink and in block capitals

Reserved for the INPI	
DATE OF SUBMISSION OF THE DOCUMENTS	-6 AUGUST 1999
NATIONAL REGISTRATION	99/10,378
DEPARTMENT OF FILING	LY
DATE OF FILING	6 AUGUST 1999

1. NAME AND ADDRESS OF THE APPLICANT OR THE REPRESENTATIVE TO WHOM THE CORRESPONDENCE IS TO BE ADDRESSED

AVENTIS PASTEUR
DPI
2, avenue du Pont PASTEUR
69007 LYON

No. of permanent power of attorney	Correspondent's references	Telephone
PG 04853	PM 9908	04 37 37 70 90

2 APPLICATION Nature of the industrial property right

☒ patent ☐ divisional application → initial application ↓

☐ utility certificate ☐ conversion of a European patent application ☐ patent ☐ utility certificate No. date

Compilation of the search report ☐ deferred ☒ immediate

The applicant, as a physical person, asks to pay the fee by instalments ☐ yes [ ] no

Title of the invention (maximum 200 characters)

Immunostimulant oligonucleotide

3. APPLICANT(S) SIREN No. 3 4 9 5 0 5 3 7 0 APE-NAF code 2 4 4 C

Name and forenames (underline the surname) or company name

AVENTIS PASTEUR

Legal form

S.A.

Nationality/Nationalities French

Full address(es)

2 avenue du Pont PASTEUR
69007 LYON.

Country

FRANCE

If insufficient space, continue on plain paper ☐

4. INVENTOR(S) The inventors are the applicants ☐ yes ☒ no If the answer is no, provide a separate designation

5. REDUCTION OF THE RATE OF FEES ☐ requested for the first time ☐ requested prior to filing; attach copy of the favourable decision

6. PRIORITY DECLARATION OR APPLICATION FOR THE BENEFIT OF THE FILING DATE OF A PRIOR APPLICATION

Country of origin	Number	Filing date	Nature of the application

7. DIVISIONS previous to the present application — No. date — No. date

8. SIGNATURE OF THE APPLICANT OR REPRESENTATIVE (name and capacity of the signatory - registration No.)

Danièle KERNEIS
European Patent & Trademark Attorney
(signature)

SIGNATURE OF THE RECEIVING OFFICIAL

(signature)
A. CHAPELANP

SIGNATURE AFTER REGISTRATION OF THE APPLICATION AT THE INPI

(illegible signature)

INPI
INSTITUT NATIONAL DE LA PROPRIETE INDUSTRIELLE

PATENT, UTILITY CERTIFICATE

DESIGNATION OF THE INVENTOR
(if the applicant is not the inventor or the sole inventor)

PATENTS ADMINISTRATIVE DIVISION
26bis, rue de Saint-Petersbourg
75800 Paris Cédex 08
Tel: 01 53 04 53 04 - Fax: 01 42 93 59 30

NATIONAL REGISTRATION NO.
99/10,378

TITLE OF THE INVENTION:

Immunostimulant oligonucleotide

THE UNDERSIGNED

PASTEUR MERIEUX Sérums et Vaccins

DESIGNATE(S) AS INVENTOR(S) (surname underlined, forenames, address):

BACHY Monique
Domaine de la Roche
F - 69440 Saint MAURICE sur DARGOIRE

SODOYER Régis
La Calmeraie
5, rue du Brulet
F - 69110 Sainte FOY les LYON

TRANNOY Emanuelle
4, rue Pauline Marie Jaricot
F - 69005 LYON

NOTE: In exceptional cases, the name of the inventor may be followed by that of the company to which he belongs (membership company) when the latter is other than the company which is the applicant or proprietor.

Date and signature(s) of the applicant(s) or of the representative

6 August 1999

(signature)
KERNEIS Danièle

IMMUNOSTIMULANT OLIGONUCLEOTIDE

The present invention relates to the domain of immunostimulants. More particularly, the invention relates to oligonucleotides capable of stimulating human cells involved in the immune system, and to the use thereof as an immunization adjuvant.

A large number of oligonucleotides have already been described in the prior art, in relation to their immunostimulant properties. Thus, application EP 0 468 520 describes immunostimulant polynucleotides consisting of a linear DNA single strand comprising from 10 to 100 nucleotides linked together according to a palindromic sequence.

According to application WO 96/02 555, the immunostimulatory activity of oligonucleotides is linked to the presence of a 5′ CG 3′ dinucleotide sequence in which neither C nor G are methylated, the immunostimulant activity being greater if the CG unit is preceded in 5′ by the dinucleotide GA and/or followed in 3′ by the dinucleotide TC or TT.

On the contrary, according to patent application WO 98/52 962, it is not necessary for the oligonucleotide sequence to be a palindrome, or for it to comprise the dinucleotide CG: in fact, the 3 oligonucleotides described in this application for use as an immunization adjuvant have the following sequences: 5′GACGTT3′, 5′GAGCTT3′, and 5′ TCCGGA 3′.

According to US patent 5,663,153, the immunostimulant activity of oligonucleotides is not linked to the sequence of the nucleotides, but to the nature of the bond between nucleotides, the presence of at least one phosphorothioate bond making it possible to induce stimulation of the immune system.

Most tests of the prior art for evaluating the immunostimulant activity of the oligonucleotides provided are carried out either in vitro, on animal cells (essentially murine cells), or in vivo on mice. However, the differences which exist between the immune system of mice and that of humans have led to differences between the results obtained on murine cells and those obtained on human cells.

Now, the pharmaceutical industry is in great need of immunostimulants which can be administered to humans, in particular in the field of vaccines.

The aim of the present invention is therefore to propose oligonucleotides capable of stimulating cells of the immune system of humans.

In order to achieve this aim, a subject of the invention is an oligonucleotide capable of stimulating human cells of the immune system, characterized in that it comprises at least one sequence 5′ T T N_1 N_2 T T 3′ in which T is thymine, and N_1 and N_2 may each represent adenine, thymine, cytosine or guanine, and in that it lacks a dinucleotide CG in which the cytosine C is not methylated.

According to one characteristic of the invention, the oligonucleotide comprises from 6 to 100 nucleotides.

According to a particular characteristic, the oligonucleotide according to the invention is characterized in that N_1 represents adenine and in that N_2 represents guanine.

According to another characteristic, the oligonucleotide according to the invention is characterized in that the 5′ T T N_1 N_2 T T 3′ unit is repeated at least once.

According to another characteristic, the oligonucleotide according to the invention is characterized in that the 5′ T T N_1 N_2 T T 3′ unit is repeated twice.

According to another characteristic, the oligonucleotide according to the invention is characterized in that the repeated 5′ T T N_1 N_2 T T 3′ units are separated by a nucleotide N_3 which may, each time, be identical or different, and which may represent A, C, T or G.

According to a particular characteristic, the oligonucleotide according to the invention is characterized in that the nucleotide N_3 separating the first two T T N_1 N_2 T T units read when the sequence is oriented 5′→3′ represents cytosine.

According to another characteristic, the oligonucleotide according to the invention is characterized in that it comprises the sequence 5′ TTAGTTCTTAGTTN_3TTAGTT 3′, in which A represents adenine, T represent thymine, G represents guanine and C represents cytosine, and in which N_3 may signify A, T, C or G.

According to another characteristic, the oligonucleotide according to the invention is capable of inducing human lymphocyte proliferation.

According to another characteristic, the oligonucleotide according to the invention is capable of increasing the expression of the activation markers CD25 and CD86 of human B lymphocytes.

According to another characteristic, the oligonucleotide according to the invention is capable of inducing the secretion of cytokines, in particular of IL 10 and Interferon γ.

A subject of the invention is also an immunization adjuvant, characterized in that it comprises at least one oligonucleotide which is capable of stimulating human cells of the immune system and which contains at least one sequence 5′ T T N_1 N_2 T T 3′ in which T is thymine, and N_1 and N_2 may each represent adenine, thymine, cytosine or guanine, the oligonucleotide lacking a CG dinucleotide sequence in which the cytosine C is not methylated.

A subject of the invention is also an immunization composition for human use, comprising at least one immunization antigen, characterized in that it also comprises at least one oligonucleotide which is capable of stimulating human cells of the immune system and which contains at least one sequence 5′ T T N_1 N_2 T T 3′ in which T signifies thymine, and N_1 and N_2 may each represent adenine, thymine, cytosine or guanine, the oligonucleotide lacking a CG dinucleotide sequence in which the cytosine C is not methylated.

The present invention will be more clearly understood upon reading the following description, with reference to figures 1 to 11 which illustrate the results obtained in the tests described in Examples 2 to 7.
In particular, figures 1 and 2 indicate the number of counts per minute obtained in the test of the example.
Figures 3 and 5 indicate the percentage of CD20+ cells expressing the CD25 marker, for the oligonucleotides obtained according to example 1. Similarly, figures 4 and 6 indicate the percentage of CD20+ cells expressing the CD86 marker.
Figure 7 indicates the number of counts per minute obtained in the test of example 4.
Figure 8 indicates the percentage of CD20+ cells expressing the CD25 marker, for the oligonucleotides obtained according to example 4. Similarly, figure 9

indicates the percentage of CD20+ cells expressing the CD86 marker.

Figure 10 indicates the number of spots measured for the secretion of interferon γ by cells stimulating the presence of the oligonucleotides having the sequences 9 to 12 described in example 4.

Figure 11 indicates the number of spots measured for the secretion of IL 10 by cells stimulated in the presence of the oligonucleotides having the sequences 9 to 12 described in example 4.

For the purposes of the present invention, the term "oligonucleotide" is intended to mean a polynucleotide comprising at least six nucleotides. Specifically, contrary to the teaching of the article entitled "CpG motifs in bacterial DNA trigger direct B-cell activation", Krieg et al., Nature 1995, it was noted that it is not necessary for the oligonucleotide to have at least 8 nucleotides. On the other hand, the upper limit of the size of the oligonucleotides is not really determined. It may, however, be noted that, the longer the oligonucleotide, the more difficult it will be to purify it during the steps of synthesis and the higher the cost price thereof. In addition, it is probable that a very long oligonucleotide will find it more difficult to penetrate cells. Thus, for the needs of the present invention, it is considered that limiting the size of the oligonucleotide to 100 nucleotides is suitable. This oligonucleotide is preferably a single-stranded oligonucleotide; it may be an oligodeoxyribonucleotide or an ologoribonucleotide. Particularly good results have been obtained using an oligodeoxyribonucleotide. The oligonucleotides which are suitable for the purposes of the invention may be in phosphodiester form or, in order to be more stable, in the form of phosphorothioates or phosphodiester/phosphorothioate hybrids. Those preferred are phosphorothioate oligonucleotides.

The oligonucleotide according to the invention is capable of stimulating human cells of the immune system. This stimulation is assessed, in particular, by lymphoproliferation or by the expression of activation markers, such as the markers CD25 and CD86 of B lymphocytes. It is possible to select the oligonucleotides of interest using tests other than those provided in the present application, on the condition, however, that they are tests which evaluate the capacity for stimulating human cells and not, as in most of the documents of the prior art, tests which evaluate the capacity for stimulating murine cells. It would, in particular, be possible to test the expression of other B lymphocyte activation markers, such as the CD69 or CD56 markers, or the expression of proliferation markers, such as the KI67 marker; tests relating to an increase in activation markers and maturation markers of dendritic cells may also be used. Similarly, tests for assessing an increase in production of certain cytokines, such as, for example, IL6, IL12, IL10, IFNγ, TNFα may also be used.

According to one characteristic of the invention, the oligonucleotide comprises at least one nucleotide sequence 5′ T T N_1 N_2 T T 3′ in which T signifies thymine, and N_1 and N_2 may each represent adenine, thymine, cytosine or guanine. This formula thus covers 16 possibilities. This sequence may be 5′-terminal or 3′-terminal, or be surrounded by other nucleotides. It may be unique or repeated several times identically within the same oligonucleotide. An oligonucleotide according to the invention may also comprise several different sequences each corresponding to the 5′ T T N_1 N_2 T T 3′ unit.

According to the invention, the oligonucleotide does not comprise a palindromic sequence. Despite this absence of palindromic sequence, such an

oligonucleotide is capable of stimulating human cells of the immune system.

According to one characteristic, the oligonucleotide according to the invention lacks a dinucleotide CG in which the cytosine is not methylated. This exclusion also applies to the N_1 N_2 unit. The ability of the oligonucleotides of the prior art to be immunostimulant has almost always been interpreted as being linked to the presence of nonmethylated CpG units (cf. in particular the article by Krieg et al. in Nature of April 1995, mentioned above), this interpretation being coherent with the observation according to which the frequency of this dinucleotide is four times greater in the genome of bacteria and of viruses than in that of vertebrates. Surprisingly, it has now been found that oligonucleotides completely lacking this dinucleotide unit are, however, entirely capable of stimulating the human immune system.

According to a particular embodiment of the present invention, the N_1N_2 unit corresponds to the dinucleotide AG, in which A signifies adenine and G signifies guanine.

According to an advantageous characteristic, the 5′ TTAGTT 3′ unit is repeated at least once in the oligonucleotide, and preferably at least twice. Even more preferably, the repeated units are separated by at least one nucleotide N_3, which represents adenine, cytosine, guanine or thymine. Within an oligonucleotide, this separation nucleotide may be always the same or be different each time. Preferably, the nucleotide separating the first 2 TTAGTT units of the oligonucleotide (taking the direction of reading to be 5′→3′) consists of cytosine.

The oligonucleotides which are particularly preferred for the purpose of the present invention are those in which the nucleotide sequences correspond to the

formula 5′ TTAGTTCTTAGTTN$_3$TTAGTT 3′, in which N$_3$ represents A, T, C or G.

According to a particular characteristic, the oligonucleotide according to the invention lacks or is low in nucleotide sequence capable of inhibiting the cells of the human immune system. In fact, in order to obtain an overall immunostimulant effect, if inhibitory or neutralizing units such as, for example, those described in application WO 98/52 581 are present, their effect must be suppressed or decreased, through the presence of a sequence with more pronounced immunostimulant effect or through the presence of a greater number of 5′ T T N$_1$ N$_2$ T T 3′ sequences.

A subject of the present invention is also an immunization adjuvant comprising at least one immunostimulant oligonucleotide having at least one 5′ T T N$_1$ N$_2$ T T 3′ unit as mentioned above. The term "immunization adjuvant" is intended to mean a product which makes it possible to increase or to modify the response of the immune system of an organism with respect to the administration of an antigen. In particular, it may be an increase in the humoral response or in the cellular response.

The action of an immunization adjuvant may also be, not an increase in the response which would occur in the absence of adjuvant, but a different orientation of the response produced: for example, orientation toward a cellular response rather than a humoral response, production of certain cytokines rather than others, production of certain antibody types or subtypes rather than others, stimulation of certain cells rather than others, etc.

The immunostimulant oligonucleotide of the present invention may be used as an immunization adjuvant whatever the nature of the antigen administered and

whatever the number of valencies used. It may be the only adjuvant used or, on the contrary, it may be one element of an adjuvant combination.

The adjuvant action of the oligonucleotide according to the invention may be obtained either when it is combined with the antigen(s) when they are administered, i.e. when they are part of the same immunization composition, or when it is administered separately from the antigen(s). It is, however, preferred to use it in the same immunization composition as the antigen(s) to be administered.

The oligonucleotide according to the invention may advantageously be administered via all the routes which can be used for an immunization composition: mucosal route or systemic route.

One of the subjects of the invention is an immunization composition comprising at least one immunostimulant oligonucleotide having a 5′ T T N_1N_2 T T 3′ sequence as described above.

An immunization composition according to the invention may be intended for immunization against a single disease or intended for immunization against several diseases. It may be a liquid or a lyophilized immunization composition. It may comprise, besides the antigens, all or some of the components conventionally present in a vaccine, such as buffers, stabilizers, preserving agents, etc. It may also comprise one or more adjuvant(s) other than those which are subjects of the present invention. It may also comprise several adjuvants which are subjects of the present invention, consisting either of oligonucleotides which all have the same 5′ T T N_1 N_2 T T 3′ unit but which differ by the nucleotides in 5′ and/or in 3′, or oligonucleotides which have different 5′ T T N_1 N_2 T T 3′ units, the sequence in 5′ and in 3′ of which are identical or different.

The immunization composition according to the invention may be intended for prophylactic administration or for therapeutic administration.

The immunization composition according to the invention may be formulated so as to optimize the adjuvant action of the oligonucleotide which is the subject of the invention. Thus, the oligonucleotide may be coupled to a lipid, such as cholesterol; it may be integrated into an emulsion of the oil/water type or formulated in the form of liposomes.

The following examples illustrate particular embodiments of the present invention.

Example 1: Oligonucleotide synthesis

15 oligonucleotides were synthesized, each having one of the following units:

5' TTAATT 3'
5' TTACTT 3'
5' TTATTT 3'
5' TTAGTT 3'
} Series A

5' TTTTTT 3'
5' TTTATT 3'
5' TTTCTT 3'
5' TTTGTT 3'
} Series T

5' TTCCTT 3'
5' TTCATT 3'
5' TTCTTT 3'
} Series C



and having 4 adenines in 5' and 5 adenines in 3'.

These oligonucleotides are synthesized using an automatic synthesizer supplied by Applied Biosystems, which uses the standard phosphoramidite chemical method and which comprises, in each cycle, an oxidation step, which is carried out using a tetraethylthiuram/acetonitrile solution, in order to obtain a phosphorothioate bond.

An oligonucleotide A15(S) which comprises only As and which is phosphorothioate throughout its length is also prepared, in the same way. This oligonucleotide is a negative control since it causes neither proliferation nor an increase in the expression of activation markers of B lymphocytes.

An oligonucleotide 3Db(S), the sequence of which is identified in patent application WO96/02555 under SEQ Id No. 15 (5'GAGAACGCTCGACCTTCGAT3'), is also prepared; this oligonucleotide comprises phosphorothioate bonds throughout its length and is used as a positive control.

All the oligonucleotides are maintained in solution in PBS buffer.

Example 2: Lymphoproliferation test

Lymphocytes are isolated from the peripheral blood of a donor by carrying out a centrifugation on a Ficoll gradient. These lymphocytes are adjusted to 2×10^6 cells/ml in culture medium (RPMI 1640 + 10% fetal calf

serum, and also glutamine, streptomycin and penicillin).

The cells are distributed into 96-well plates (round-bottomed) in 100 µl, i.e. 2×10^5 cells per well. 100 µl of a 4 µM solution of oligonucleotides to be tested produced in Example 1 (a single type of oligonucleotide per well) are then added in order to obtain a 2 µM final concentration.

The cells are incubated for 48 to 72 hours.

Tritiated thymidine (Amersham TRK 120) is diluted in culture medium and then distributed in the plates in the proportion of 1 µCi per well in 50 µl. After incubation for 7 to 8 hours in an incubator (5% CO_2, 37°C), the plates can be frozen at -80°C and treated later.
Using a "Harvester", the content of the wells is harvested onto Unifilter GF/C plates and 6 washes in distilled water are carried out followed by a wash in 70% ethanol in order to precipitate the DNA.
After drying the plates, 25 µl of liquid scintillant (Microscint-40, Packard) are distributed into each well and allow the radioactivity (radiation emitted by tritium) to be quantified by measuring the number of counts/minute (cpm) emitted by each well on a Top Count counter (Packard).

The results obtained for each of the oligonucleotides tested are represented on figures 1 and 2, which indicate, for each oligonucleotide tested, the number of counts per minute; it is noted that all the nucleotides according to the invention have a result which is clearly greater than the result obtained with the medium alone or the negative control A15(S), which means that they are all capable of stimulating lymphocyte proliferation.

Example 3:

Test relating to activation markers

The test is carried out using lymphocytes isolated from a donor as described in the previous example, and adjusted to 2×10^6 cells/ml in the same culture medium.

The cells are then distributed into 12-well plates in a volume of 2 ml, i.e. 4×10^6 cells/well. An amount of oligonucleotides to be tested prepared in Example 1 (1 oligonucleotide/well) which is sufficient to obtain a 2 μM oligonucleotide concentration is added to each well. The cells are then incubated for 72 hours at 37°C. The cells are then double-labeled using CD25PE/CD20FITC or CD86PE/CD20FITC, followed by analysis on a FACScan. The results obtained are illustrated on figures 3, 4, 5 and 6, which represent, for each oligonucleotide tested, the percentage of B cells (CD20+) which express the CD25 receptor (those which are CD25+) or the CD86 marker (those which are CD86+). The results represented on figures 3 and 4 were obtained in a test carried out at a different time from the test for which the results are illustrated on figures 5 and 6, which explains the difference in the order of magnitude of the results obtained. Specifically, in this type of manipulation, the tests are very variable from one assay to the other, and only the results obtained in the same test are comparable with one another, hence the necessity of including, in each test, an oligonucleotide-control and also an assay of the medium alone.

It is noted that all the oligonucleotides which are subjects of the invention activate the B lymphocytes which express their activation marker CD25 and CD86.

Example 4:

A series of 16 oligonucleotides having the following sequences are prepared in the same way as in example 1:

Seq Id 1 : 5′ TTAGTTATTAGTTATTAGTT 3′
Seq Id 2 : 5′ TTAGTTATTAGTTTTTAGTT 3′
Seq Id 3 : 5′ TTAGTTATTAGTTCTTAGTT 3′
Seq Id 4 : 5′ TTAGTTATTAGTTGTTAGTT 3′
Seq Id 5 : 5′ TTAGTTTTTAGTTATTAGTT 3′
Seq Id 6 : 5′ TTAGTTTTTAGTTTTTAGTT 3′
Seq Id 7 : 5′ TTAGTTTTTAGTTCTTAGTT 3′
Seq Id 8 : 5′ TTAGTTTTTAGTTGTTAGTT 3′
Seq Id 9 : 5′ TTAGTTCTTAGTTATTAGTT 3′
Seq Id 10 : 5′ TTAGTTCTTAGTTTTTAGTT 3′
Seq Id 11 : 5′ TTAGTTCTTAGTTCTTAGTT 3′
Seq Id 12 : 5′ TTAGTTCTTAGTTGTTAGTT 3′
Seq Id 13 : 5′ TTAGTTGTTAGTTATTAGTT 3′
Seq Id 14 : 5′ TTAGTTGTTAGTTTTTAGTT 3′
Seq Id 15 : 5′ TTAGTTGTTAGTTCTTAGTT 3′
Seq Id 16 : 5′ TTAGTTGTTAGTTGTTAGTT 3′

These oligonucleotides are of the phosphorothiate type throughout their length.

Example 5:

The capacity of the oligonucleotides prepared in example 4 to induce human lymphocyte proliferation is evaluated using a lymphoproliferation test such as that described in example 2. In the same way as in example 2, the oligonucleotide concentration per well is 2 µM and the controls consist of the medium alone, the oligonucleotide A15(S) and also the oligonucleotide 3Db(S).
The results obtained, expressed in counts per minute, are represented in figure 7, which shows that all the oligonucleotides according to the invention are capable

of inducing lymphocyte proliferation and that particularly good results are obtained when the sequences of the oligonucleotides are those identified by Seq Ids 9 to 12, i.e. when cytosine separates the first 2 TTN_1N_2TT units of the oligonucleotide.

Example 6:

The capacity of the oligonucleotides prepared in example 4 to induce the expression of the activation markers CD25 and CD86 of B lymphocytes is evaluated. This evaluation is carried out using the test described in example 3. The results obtained with the oligonucleotides prepared according to example 4 are represented on figures 8 and 9, which illustrate the percentages of B cells (CD20+) which also express the CD25 marker (figure 8) or the CD86 marker (figure 9).
The results obtained in this test confirm those obtained in the lymphoproliferation test: all the oligonucleotides according to the invention induce the expression of activation markers of human B lymphocytes; particularly good results are obtained when the first 2 TTN_1N_2TT units of the oligonucleotide are separated by cytosine.

Example 7:

The capacity of the oligonucleotides according to the present invention to induce the secretion of cytokines is evaluated.
For this evaluation, lymphocytes are isolated from the peripheral blood of a donor, by carrying out a centrifugation on a Ficoll gradient. These lymphocytes are adjusted to 2×10^6 cells/ml in culture medium (AIM V medium + streptomycin + penicillin).
ELISPOT 96-well plates (flat-bottomed made of nitrocellulose) are preincubated the day before with a solution of antibodies for capturing cytokines (IL-10

or IFNγ depending on the test carried out), and then saturated with culture medium.

100 µl of cells are then distributed into the ELISPOT plates, i.e. 2×10^5 cells per well, and 100 µl of a 4 µM solution of oligonucleotides to be tested, produced according to example 4, are then added (only one type of oligonucleotide per well) in order to obtain a 2 µM final concentration. The test is carried out with the oligonucleotides having the sequences described under Seq Id 9, Seq Id 10, Seq Id 11 and Seq Id 12.

The plates are incubated at 37°C, under an atmosphere of 5% of CO_2. After incubating for 72 hours, the cells are removed by washing in the presence of detergent (1% Tween) and the cytokines attached to the capture antibodies are revealed by successively adding biotinylated detection antibodies (anti-IL-10 or anti-IFNγ depending on the test carried out), streptavidin-HRP and the substrate AEC.

The spots (1 spot corresponding to 1 cytokine-secreting cell) are counted using an automatic counter. The results are expressed as number of spots (number of secreting cells) per million cells.

The results obtained for each of the oligonucleotides tested are represented on figures 10 and 11, which indicate, for each oligonucleotide tested, the number of cytokine-secreting cells per million total cells; it is noted that all the oligonucleotides according to the invention have a result which is clearly greater than the result obtained with the medium alone or the negative control A15(S), which means that they are all capable of inducing the secretion of cytokines, in particular of IL 10 and of interferon γ.

SEQUENCE LISTING

<110> PASTEUR MERIEUX SERUMS & VACCINS

<120> IMMUNOSTIMULANT OLIGONUCLEOTIDE

<130> PM9908FR

<140>
<141>

<160> 16

<170> PatentIn Ver. 2.1

<210> 1
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 1
ttagttatta gttattagtt 20

<210> 2
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 2
ttagttatta gtttttagtt 20

<210> 3
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial sequence description:
oligonucleotide
<400> 3
ttagttatta gttcttagtt 20

<210> 4
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 4
ttagttatta gttgttagtt 20

<210> 5
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 5
ttagttttta gttattagtt 20

<210> 6
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 6
ttagttttta gttttagtt 20

<210> 7
<211> 20
<212> DNA

<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 7
ttagttttta gttcttagtt 20

<210> 8
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 8
ttagttttta gttgttagtt 20

<210> 9
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 9
ttagttctta gttattagtt 20

<210> 10
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 10
ttagttctta gttttagtt 20

<210> 11
<211> 20

<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 11
ttagttctta gttcttagtt 20

<210> 12
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 12
ttagttctta gttgttagtt 20

<210> 13
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 13
ttagttgtta gttattagtt 20

<210> 14
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 14
ttagttgtta gttttagtt 20

<210> 15
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 15
ttagttgtta gttcttagtt 20

<210> 16
<211> 20
<212> DNA
<213> Artificial sequence
<220>
<223> Artificial sequence description:
oligonucleotide
<400> 16
ttagttgtta gttgttagtt 20

Claims

1. An immunostimulant, characterized in that it comprises at least one nucleotide sequence having the following formula 5′ T T N_1 N_2 T T 3′, in which T signifies thymine, and N_1 and N_2 may each represent adenine, thymine, cytosine or guanine, and in that it lacks a dinucleotide CG in which the cytosine C is not methylated.

2. The oligonucleotide as claimed in claim 1, characterized in that it comprises from 6 to 100 nucleotides.

3. The oligonucleotide as claimed in claim 1, characterized in that N_1 represents adenine and in that N_2 represents guanine.

4. The oligonucleotide as claimed in one of the preceding claims, characterized in that the 5′ T T N_1 N_2 T T 3′ unit is repeated at least once.

5. The oligonucleotide as claimed in the preceding claim, characterized in that the 5′ T T N_1 N_2 T T 3′ uni is repeated twice.

6. The oligonucleotide as claimed in either of claims 4 and 5, characterized in that the repeated 5′ T T N_1 N_2 T T 3′ units are separated by a nucleotide N_3 which may, each time, be identical or different, and which may represent A, C, T or G.

7. The oligonucleotide as claimed in the preceding claim, characterized in that the nucleotide N_3 separating the first 2 T T N_1 N_2 T T units read when the sequence is oriented 5′→3′ represents cytosine.

8. The oligonucleotide as claimed in one of the preceding claims, characterized in that it comprises the sequence 5′ TTAGTTCTTAGTTN$_3$TTAGTT 3′ in which A represents adenine, T represents thymine, G represents guanine and C represents cytosine, and in which N_3 may signify A, T, C or G.

9. The oligonucleotide as claimed in one of the preceding claims, characterized in that it is capable of inducing human lymphocyte proliferation.

10. The oligonucleotide as claimed in any one of the preceding claims, characterized in that it is capable of inducing the secretion of cytokines.

11. The oligonucleotide as claimed in the preceding claim, characterized in that it is capable of inducing the secretion of IL 10.

12. The oligonucleotide as claimed in claim 10, characterized in that it is capable of inducing the secretion of Interferon γ.

13. The oligonucleotide as claimed in one of the preceding claims, characterized in that it is capable of increasing the expression of the activation markers CD25 and CD86 of human B lymphocytes.

14. The use of an oligonucleotide as claimed in one of the preceding claims, for producing a medicinal product.

15. The use of an oligonucleotide as claimed in one of claims 1 to 10, for producing a human immunostimulant.

16. The use of an oligonucleotide as claimed in one of claims 1 to 10, for producing an immunostimulant adjuvant.

17. The use of an oligonucleotide as claimed in one of claims 1 to 10, for producing an immunization composition.

18. An immunization composition for human use, comprising at least one immunization antigen, characterized in that it also comprises at least one oligonucleotide as claimed in one of claims 1 to 10.



Figure 1



Figure 2



Figure 3



Figure 4



Figure 5



Figure 6


30000
25000
20000
15000
10000
5000
0
CPM
Medium
A15
3DbS
SEQ 1
SEQ 2
SEQ 3
SEQ 4
SEQ 5
SEQ 6
SEQ 7
SEQ 8
SEQ 9
SEQ 10
SEQ 11
SEQ 12
SEQ 13
SEQ 14
SEQ 15
SEQ 16
SEQ17

Figure 7



Figure 8



Figure 9



Figure 10



Figure 11